Clinical observation of umbilical cord mesenchymal stem cell treatment of severe systolic heart failure

Abstract

ABSTRACT. The aim of this study was to evaluate the effectiveness of umbilical cord mesenchymal stem cells (MSCs) in the treatment of chronic systolic heart failure. Fifty-nine hospitalized patients with heart failure were randomly divided into a treatment group (30 patients) and a control group (29 patients). The treatment group received treatment with medication as well as intracoronary transplantation of umbilical cord MSCs, and the control group, only medication. The cardiac structure, function change, and rehospitalization and mortality rates of the 2 groups were observed before and 1 and 6 months after treatment. One month after the transplantation of umbilical cord MSCs, the incidence of fatigue, chest tightness, and dyspnea was high in the treatment group. The 6-min walking distance of the treatment group was found to be significantly higher than that of the control group (P < 0.05); in addition, the NT-proBNP level, left ventricular ejection fraction, and mortality rate of the treatment group were statistically lower than those of the control group (P < 0.05). Readmission rates showed a downward trend, but the difference was not statistically significant (P > 0.05). Using umbilical cord MSCs in the treatment of congestive heart failure 3011 Treatment of severe systolic heart failure ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (2): 3010-3017 (2015) can help improve cardiac remodeling and cardiac function and reduce the mortality rate.

Safety and Efficacy of Adult Stem Cell Therapy for Acute Myocardial Infarction and Ischemic Heart Failure (SafeCell Heart): A Systematic Review and Meta-Analysis

“…Of the 23 included studies, 11 evaluated AMI ( n = 509 patients) and 12 evaluated IHF ( n = 639 patients) (Table ). Of these studies, eight were RCTs that evaluated AMI ( n = 429 patients) and five were RCTs that evaluated IHF ( n = 472 patients) . The number of evaluated patients who received MSCs ranged from 9 to 58 patients for the AMI studies and from 6 to 107 patients for the IHF studies.…”

“…Secondary outcomes assessed included safety or efficacy . Of the IHF studies, four studies evaluated safety , four studies evaluated efficacy , and four studies evaluated both as the primary outcome. Secondary outcomes assessed included efficacy or both efficacy and safety .…”

“…Of the 11 studies evaluating AMI, 7 studies used autologous MSCs and 4 studies used allogeneic MSCs (Table ). Of the 12 studies evaluating IHF, 9 studies used autologous MSCs and 3 studies used allogeneic MSCs . The majority of studies (18/23) used bone‐marrow derived MSCs and the remaining used either MSCs that were umbilical cord‐derived (4/23) or adipose tissue‐derived (1/23) .…”

“…Of the 12 studies evaluating IHF, 9 studies used autologous MSCs and 3 studies used allogeneic MSCs . The majority of studies (18/23) used bone‐marrow derived MSCs and the remaining used either MSCs that were umbilical cord‐derived (4/23) or adipose tissue‐derived (1/23) . Comparisons consisted of standard treatment (5/23) , saline (4/23) , heparinized saline (1/23) , historical control (1/23) , vehicle placebo (3/23) , sham procedure (1/23) , plasmalyte A (1/23) , or the study did not include a comparison group (5/23) (Table ) .…”

“…One study compared allogeneic MSCs to autologous MSCs and did not use a control group . The number of allogeneic donors were reported in four studies , while three studies did not report this information.…”